In addition, ESMO has currently recommended that in advanced NSCLC cases, molecular testing, including EGFR and BRAF mutations, METex14 skipping mutations, ALK and ROS-1 fusions, RET rearrangements, and PD-L1 expression should be conducted [42]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.